TABLE 1.
Clinical outcomes of dogs following allogeneic hematopoietic transplantation
| ID | Transplantation Conditions | Samples | Onset of GVHD (Days) | ICOS Eval. (Days) | GVHD* |
|---|---|---|---|---|---|
| H236† | 4.5 Gy TBI + CSP (35 days)/MMF (28 days) DLA-haploidentical donor |
PB | 176/262 | 271 | Skin |
| H457 | 9.2 Gy TBI + CSP (120 days)/MMF (180 days) DLA-haploidentical donor |
PB, LN, SP | 213 | 220 | Skin |
| H316 | 9.2 Gy TBI + CSP (80days)/MTX (days 1, 3, 6) DLA-nonidentical donor |
PB, LN, SP | 93 | 103 | Skin/Liver |
| H432 | 9.2 Gy TBI + CSP (80 days)/MTX (days 1, 3, 6) DLA-nonidentical donor |
PB | 95 | 107 | Skin/Liver |
| H470 | 9.2 Gy TBI + CSP (100 days)/MTX (days 1, 3, 6, 11) DLA-nonidentical donor |
PB, LN, SP | 133 | 146 | Skin |
| H479 | 9.2 Gy TBI + CSP (80 days)/MTX (days 1, 3, 6) DLA-nonidentical donor |
PB, LN, SP | 34 | 36 | Liver |
| H481 | 9.2 Gy TBI + CSP (80 days)/MTX (days 1, 3, 6) DLA-nonidentical donor |
PB, LN, SP | 104 | 111 | Skin |
| H348 | 9.2 Gy TBI + CSP (100 days)/MTX (days 1, 3, 6, 11) DLA-nonidentical donor |
PB, LN, SP | ND | 181 | ND |
| H495 | 4.5 Gy TBI + CSP (35 days)/MMF (28 days) DLA-haploidentical donor |
PB | ND | 76 | ND |
| H371 | 4.5 Gy TBI + CSP (35 days)/MMF (28 days) DLA-haploidentical donor |
PB | ND | 252 | ND |
*
GVHD was confirmed by the clinical manifestation and histopathology evaluation
TBI, total body irradiation; CSP, cyclosporine; MMF, mycophenolate mofetil MTX, methotrexate; DLA, dog leukocyte antigen; PB, peripheral blood; LN, lymph node; SP, spleen; ND, not detected.
†
H236 presented cutaneous GVHD on day 176 after transplantation and was treated with MMF (5 mg/kg BID) and CSP (10 mg/kg, BID) to resolve the reaction. Immunosuppression ceased on day 258 and cutaneous GVHD verified on day 262 after transplantation.